Key Highlights

• On 12 August 2026, HLS reported second-quarter Revenue of about $14.673 million, up about 3.5% from about $14.171 million a year earlier.
• Adjusted Earnings before interest, tax, Depreciation and Amortisation were about $4.663 million, down slightly from about $5.170 million, and the company recorded a net loss of about $1.020 million, or about $0.03 per share.
• Modest revenue growth of about 3.5% reflects a mature core product, Clozaril, offset by a fast-growing cardiovascular franchise, with Vascepa up about 17.9% and the overall cardiovascular portfolio up about 25%.
• Adjusted earnings remain solid at about $4.663 million, and Operating Cash Flow is healthy and…